GlassScriptPhysician profile
Jody James Decastro
NPI 1457633943
$1,803.63
in general payments reported to CMS, 2019-2025
28 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $208 · 2023: $677 · 2024: $420 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $257.25 | 2022-2025 | Prolastin-C Liquid |
| Abbvie INC. | $248.94 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $155.02 | 2022-2025 | Lokelma, Airsupra, Farxiga |
| Novo Nordisk INC | $148.13 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $138.19 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $94.82 | 2022-2024 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $62.91 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $61.42 | 2022-2024 | |
| Verona Pharma, INC. | $56.48 | 2025 | Ohtuvayre |
| Amgen INC. | $56.31 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $53.58 | 2025 | |
| Sk Life Science, INC. | $45.92 | 2025 | |
| Boston Scientific Corporation | $43.28 | 2025 | Watchman Flx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.03 | 2025 | Caplyta |
| Astellas Pharma US INC | $39.30 | 2023 | Myrbetriq, Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $38.14 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.47 | 2022 | |
| Exact Sciences Corporation | $32.80 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $31.06 | 2025 | Auvelity |
| Shield Therapeutics INC | $25.82 | 2023 | Accrufer |
| Phathom Pharmaceuticals, INC. | $24.02 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $18.79 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $16.83 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $16.64 | 2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $16.19 | 2025 | Trintellix |
| Dexcom, INC. | $15.78 | 2023 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $15.77 | 2025 | |
| Mylan Specialty L.P. | $15.74 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Decastro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.